Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

C. Turner, Nicholas; Dent, Rebecca; O’Shaughnessy, Joyce; Kim, Sung‐Bae; J. Isakoff, Steven; H. Barrios, Carlos; Saji, Shigehira; Bondarenko, Igor; Nowecki, Zbigniew; Lian, Qinshu; Reilly, Sarah-Jayne; Hinton, Heather; Wongchenko, Matthew; Kovic, Bruno; Mani, Aruna; Oliveira, Mafalda

doi:10.1007/s10549-021-06450-x

Public

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Published in Breast Cancer Research and Treatment • Dec 3, 2021

Authors:

Nicholas C. Turner

Rebecca Dent

Joyce O’Shaughnessy

Abstract

Abstract Purpose PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib–paclitaxel in PI3K pathway-mutant HR+ unresectable locally advanced/metastatic breast cancer (aBC). Methods Cohort B of the randomized, double-...

Subject

Medicine

Breast cancer

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!